Skip to main content
Biotest AG logo

Biotest AG — Investor Relations & Filings

Ticker · BIO3 ISIN · DE0005227201 LEI · 529900JVX7RPXBLYUD89 F Manufacturing
Open in API
Filings indexed 1,148 across all filing types
Latest filing 2025-12-19 Regulatory Filings
Country DE Germany
Listing F BIO3

About Biotest AG

https://www.biotest.com/de/en/index.cfm

Biotest AG is a global company that develops, manufactures, and supplies plasma protein products and biotherapeutic drugs. Sourced from human blood plasma, its products are primarily used in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. The portfolio includes immunoglobulins (e.g., Intratect), coagulation factors, and albumins designed to treat severe and chronic diseases such as immune deficiencies, haemophilia, and coagulation disorders. The company manages the entire value chain from clinical development to sales and is advancing a pipeline of new treatments, including next-generation immunoglobulins (BT595) and fibrinogen concentrates (BT524). Biotest also provides Human Serum Albumin for use as a multifunctional excipient in pharmaceutical and diagnostic applications.

Recent filings

Filing Released Lang Actions
Biotest announces US FDA approval of Grifols FesiltyTM (fibrinogen, human-chmt)
Regulatory Filings Classification · 95% confidence The document is a corporate press release announcing the US FDA approval of a new product (Fesilty) developed by Biotest AG. It provides details on the product, the manufacturing facility, and the strategic implications for the Grifols group. As it is a general corporate news announcement regarding regulatory approval and does not fit into specific categories like financial reports, M&A, or shareholder voting, it falls under the 'Regulatory Filings' (RNS) category as a general corporate news dissemination.
2025-12-19 English
§§ 264 Abs. 3, 264b HGB zum Geschäftsjahr vom 01.01.2025 bis zum 31.12.2025
Audit Report / Information Classification · 95% confidence The document contains shareholder resolutions (Gesellschafterbeschluss) for several subsidiaries of Biotest AG (Biotest Grundstücksverwaltungs GmbH, Biotest Pharma GmbH, and Plasma Service Europe GmbH) regarding the application of exemption provisions under § 264 Abs. 3 HGB. These provisions allow subsidiaries to be exempted from certain financial reporting requirements (like publishing annual reports or management reports) if they are included in a parent company's consolidated financial statements. Since these are formal regulatory filings regarding corporate governance and financial reporting exemptions, and do not fit into specific categories like earnings releases or investor presentations, 'RNS' (Regulatory Filings) is the most appropriate classification. FY 2025
2025-12-01 German
Biotest obtains approval for new human fibrinogen Prufibry in Germany
Regulatory Filings Classification · 100% confidence The document is a press release issued by Biotest AG announcing the regulatory approval of a new product, Prufibry, in Germany. It details the clinical background, manufacturing, and strategic outlook related to this specific product approval. As it is a general corporate news announcement regarding regulatory developments that does not fit into specific financial reporting categories like 10-K or IR, it is classified as a Regulatory Filing (RNS).
2025-11-13 English
Biotest AG: Extraordinary general meeting convened again at the request of Grifols S.A.
AGM Information Classification · 98% confidence The document is a corporate news announcement regarding the convocation of an Extraordinary General Meeting (EGM) by Biotest AG. It details the request from a major shareholder (Grifols S.A.) and the subsequent decision by the Management Board to hold the meeting on a specific date to discuss a change in legal form. While it relates to an EGM, it is a press release/corporate news announcement rather than the meeting materials themselves or the voting results. Given the nature of the announcement regarding the scheduling and purpose of a future meeting, it fits best as a general regulatory announcement (RNS) or corporate news release.
2025-11-07 English
Biotest AG: Cancellation of the extraordinary general meeting on 28 October 2025
AGM Information Classification · 95% confidence The document is a corporate news announcement regarding the cancellation of an extraordinary general meeting (EGM) and the withdrawal of a convocation request by a majority shareholder. While it pertains to meeting logistics, it does not contain the actual materials for an AGM (AGM-R) or voting results (DVA). It is a regulatory announcement regarding corporate governance and meeting status, which fits best under the 'Regulatory Filings' (RNS) category as it is a general corporate news dissemination.
2025-10-23 English
Biotests Yimmugo launches in the United States
Regulatory Filings Classification · 100% confidence The document is a press release announcing the product launch of 'Yimmugo' in the United States by Biotest AG. It does not contain financial statements, audit reports, or regulatory filings, but rather serves as a corporate news announcement regarding business operations and product expansion. As it does not fit into specific categories like 10-K, IR, or M&A, it falls under the general regulatory/corporate news category.
2025-10-09 English

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.